ProMIS Neurosciences Issues Chairman’s Memorandum
TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
- TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
- We are in a new era in the fight against Alzheimers, ALS, and other neurodegenerative diseases, stated Eugene Williams, Executive Chairman of ProMIS Neurosciences.
- The Chairmans memorandum highlights the recent FDA accelerated approval of Biogens Aduhelm (aducanumab) which now provides a regulatory path to approval in AD, opening the door to development of next generation therapies selectively targeting the pathogenic forms of amyloid-beta.
- ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.